A.O. Moscati
Welcome,         Profile    Billing    Logout  
 7 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gridelli, Cesare
STAD-1, NCT00526396 / 2006-003995-36: Small Cell Lung Cancer Toxicity Adjusted Dosing Study

Active, not recruiting
3
160
Europe
cisplatin, etoposide
National Cancer Institute, Naples
Small Cell Lung Cancer
12/23
12/23
BEVERLY, NCT02633189 / 2015-002235-17: Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Active, not recruiting
3
200
Europe
Erlotinib, Bevacizumab
National Cancer Institute, Naples, Roche S.p.A. - Italia, Roche Molecular Systems, INC
Non-squamous Non-small Cell Lung Cancer
12/23
07/24
NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
MILES-3, NCT01405586 / 2009-013540-36: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer

Active, not recruiting
3
299
Europe
Gemcitabine, Cisplatin
National Cancer Institute, Naples
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
11/24
11/24
MILES-4, NCT01656551 / 2012-000164-25: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer

Active, not recruiting
3
232
Europe
Gemcitabine, Pemetrexed, Cisplatin
National Cancer Institute, Naples
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
11/24
11/24
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy

Active, not recruiting
2/3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
10/24
10/25
NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
300
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, Belrestotug, EOS884448, GSK4428859A, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
01/25
01/28
NCT06270602: The ONCOCAMP Study

Recruiting
N/A
15000
Europe
Data collection (retrospective), Data collection (prospective)
National Cancer Institute, Naples
Oncology
07/24
07/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26

Download Options